A Stage IV Malignant Melanoma Drug That Increases Overall Survival Would Earn a Higher Patient Share in the U.S. Than in Europe
Posted on: Monday, 19 January 2009, 07:00 CST
Ipilimumab Will Earn Decision Resources' Clinical Gold Standard for Stage IV Malignant Melanoma in 2012, According to a New Report from Decision Resources
The new report entitled Malignant Melanoma (Stage IV): Emerging Therapies Must Increase Overall Survival over Dacarbazine to Attain High Patient Share finds that clinical data and the opinions of interviewed thought leaders indicate that Bristol-Myers Squibb/Medarex's ipilimumab has advantages over dacarbazine in the attribute of median overall survival. Following its approval in 2010 for the indication, ipilimumab will earn Decision Resources' proprietary clinical gold standard for stage IV malignant melanoma from 2012 to 2017.
"Ipilimumab has competitive advantages in efficacy and has been shown, in combination with dacarbazine, to almost double median overall survival when compared to Schering-Plough's Temodar, our clinical gold standard in 2008 for stage IV malignant melanoma," said Decision Resources Analyst
About the Report
Malignant Melanoma (Stage IV): Emerging Therapies Must Increase Overall Survival over Dacarbazine to Attain High Patient Share is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
- Angiomax(R) Reduced Cardiac Mortality By 43 Percent and Improved Overall Survival By 31 Percent at One-Year in HORIZONS-AMI Trial
- VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
- Study of VIDAZA(R) in Higher-Risk Patients With Myelodysplastic Syndromes Reports Improved Overall Survival
- EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival As Predictor of Improved Overall Survival
- Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival
- ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
- Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
- Clinical Cancer Research Publishes Paper Comparing CTCs to Imaging in Predicting Overall Survival in Metastatic Breast Cancer
- ERBITUX(R) Data on Locoregional Control and Overall Survival in Phase III Head and Neck Cancer Study Presented at AACR-NCI-EORTC Meeting
 |
 |
User Comments (0)
RSS Feeds